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Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset
Still’s disease (AOSD).
Objectives: To evaluate the efficacy and safety of anakinra (ANA) and canakinumab
(CAN) in a large group of AOSD patients.
Methods: Data on clinical, serological features, and concomitant treatments were
retrospectively collected at baseline and after 3, 6, and 12 months from AOSD patients
(Yamaguchi criteria) referred by 18 Italian centers. Pouchot’s score was used to evaluate
disease severity.
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Results: One hundred forty patients were treated with ANA; 4 were subsequently
switched to CAN after ANA failure. The systemic pattern of AOSD was identified in 104
(74.2%) of the ANA-treated and in 3 (75%) of the CAN-treated groups; the chronic-
articular type of AOSD was identified in 48 (25.8%) of the ANA-treated and in 1
(25%) of the CAN-treated groups. Methotrexate (MTX) was the most frequent disease
modifying anti-rheumatic drug (DMARD) used before beginning ANA or CAN [91/140
(75.8%), 2/4 (50%), respectively]. As a second-line biologic DMARD therapy in 29/140
(20.7%) of the patients, ANA was found effective in improving all clinical and serological
manifestations (p < 0.0001), and Pouchot’s score was found to be significantly reduced
at all time points (p < 0.0001). No differences in treatment response were identified
in the ANA-group when the patients were stratified according to age, sex, disease
pattern or mono/combination therapy profile. ANA primary and secondary inefficacy at
the 12-month time point was 15/140 (10.7%) and 11/140 (7.8%), respectively. Adverse
events (AEs) [mainly represented by in situ (28/47, 59.5%) or diffuse (12/47, 25.5%)
skin reactions and infections (7/47, 14.8%)] were the main causes for discontinuation.
Pouchot’s score and clinical and serological features were significantly ameliorated at
all time points (p < 0.0001) in the CAN-group, and no AEs were registered during CAN
therapy. Treatment was suspended for loss of efficacy only in one case (1/4, 25%).
Conclusion: This is the largest retrospective observational study evaluating the efficacy
and safety of IL-1 inhibitors in AOSD patients. A good response was noted at 3 months
after therapy onset in both the ANA- and CAN-groups. Skin reaction may nevertheless
represent a non-negligible AE during ANA treatment.
Keywords: Adult-onset Still’s disease, treatment, interleukin (IL)-1, anakinra, canakinumab
INTRODUCTION
Adult-onset Still’s disease (AOSD) is a rare multisystemic
inflammatory disorder predominantly affecting young adults,
with an estimated annual incidence of 0.16–0.4 per 100,000
persons globally (Jamilloux et al., 2015; Sfriso et al., 2016). Various
genetic, infectious and environmental factors seem to interact
triggering a systemic autoinflammatory response in predisposed
individuals. A dysregulation of cytokine-mediated pathways, in
particular those linked to interleukin (IL)-1, IL-6, IL-18, tumor
necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) (Fujii et al.,
2001; Giampietro and Fautrel, 2012) has been hypothesized.
Adult-onset Still’s disease is clinically characterized by
daily high spiking fever, evanescent maculopapular skin
rash, arthritis, musculoskeletal symptoms, sore throat and
hepatosplenomegaly. Cardiopulmonary manifestations and
significant liver dysfunctions are only rarely present. Central
nervous system (CNS) and renal involvement has, likewise, been
described only in very few case reports (Gerfaud-Valentin et al.,
2014a). Typical laboratory findings include marked leukocytosis
with neutrophilia, hyperferritinemia, high liver enzymes, and
elevated acute-phase reactants such as erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP).
The clinical presentation of AOSD can be distinguished into
two phenotypes: a highly symptomatic, feverish, systemic pattern
and a chronic articular profile showing features of polyarthritis.
AOSD treatment, which essentially remains empirical, is based
on small retrospective case series studies (Jamilloux et al.,
2015). Non-steroidal anti-inflammatory drugs (NSAIDs) and
glucocorticoids are generally used as a first-line treatment,
in particular for musculoskeletal manifestations and fever.
Disease-modifying anti-rheumatic drugs (DMARDS), such as
methotrexate, azathioprine, and leflunomide, are often used in
the attempt to reduce the quantity of corticosteroids being
administered. Intravenous immunoglobulin, anti-TNF-α drugs,
such as etanercept, infliximab and adalimumab, as well as anti-
IL-6 agents, i.e., tocilizumab, also appear to adequately control
the disease in non-responders to conventional therapy (Cefle,
2005; Fautrel et al., 2005; Kim et al., 2012). These treatments
may nevertheless show variable efficacy and/or may be linked to
potentially severe side effects.
Increasing evidence regarding the global efficacy of IL-1
inhibitors (IL-1-INH), such as Anakinra (ANA; IL-1 receptor
antagonist) and Canakinumab (CAN; monoclonal anti-IL-1β
antibody) has been collected from refractory systemic and
articular AOSD patients (Kontzias and Efthimiou, 2012; Ortiz-
Sanjuán et al., 2015). ANA is a recombinant, non-glycosylated
form of human IL-1 receptor antagonist; since it has a very short
half-life, daily subcutaneous administrations are necessary. CAN,
which is a human anti-IL-1β monoclonal antibody, has a longer
half-life.
In August 2016, the European Commission extended the
license approval of CAN to treat active Still’s disease including
AOSD and Systemic Juvenile Idiopathic Arthritis (SJIA). The
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decision reached in the light of evidence supporting the concept
of a Still’s disease continuum including both the juvenile and
adult onset forms (Nirmala et al., 2015) and as the scientific
comunity awaits the results of an ongoing trial (NCT02204293).
The current study aimed to examine the use of IL-1-INH
in a large number of Italian patients with AOSD, found to
be refractory to other therapies. A nationwide cross-sectional
observational study promoted by the Italian Group of Study on
Autoinflammatory Diseases and endorsed by the Italian Society
of Rheumatology (SIR) was thus conducted to gather information
about their efficacy and their effect on clinical features and
inflammatory markers during treatment.
MATERIALS AND METHODS
Patients and Data Collection
Demographic, clinical, and therapeutic data were retrospectively
collected from AOSD patients attending 18 Italian University-
Hospital centers. The patients were considered eligible if
they were adults with AOSD diagnosed in accordance with
Yamaguchi’s criteria (Yamaguchi et al., 1992) (Table 1) and being
treated with IL-1-INH after failure of therapy based on NSAIDs
and immunosuppressive drugs, such as steroids and DMARDs,
and in some cases other biologic agents.
Attending physicians provided retrospective anonymous
information from medical records, which were entered into a
database, regarding the patients’ clinical and laboratory data, the
therapies prescribed to manage AOSD including all those prior to
IL-1-INH, response to ANA or CAN, adverse events (AEs), and
the effect on clinical symptoms 3, 6, or 12 months after IL-1-INH
therapy was begun.
The study was carried out in accordance with Good Clinical
Practice, the Declaration of Helsinki and the recommendations
of the local Ethical Committee rules of all participating centers.
Definition of Clinical and Laboratory
Criteria
In accordance with the established definition, the disease was
considered the systemic form if the patient primarily showed
marked increase in inflammatory markers, hyperferritinemia,
and multi-organ involvement. The disease was considered the
chronic form if involvement was prevalently polyarticular and
the patient presented low levels of inflammatory markers
TABLE 1 | Yamaguchi criteria (Yamaguchi et al., 1992).
Major criteria Minor criteria
(1) Fever ≥39◦C (≥1 week)
(2) Arthralgia (≥2 weeks)
(3) Typical rash
(4) Leukocytosis (≥10 000/mm3)
with ≥ 80% of granulocytes
(1) Sore throat
(2) Lymphadenopathy
and/or splenomegaly
(3) Liver dysfunction
(4) Negative RF and ANA
Diagnosis requires ≥5 criteria including at least 2 or more major criteria. Infections,
malignancies, and other rheumatic diseases must be excluded. RF, rheumatoid
factor; ANA, antinuclear antibody.
and erosive damage. Disease severity was determined using a
modified Pouchot’s score (range 0–12) (Rau et al., 2010), which
considers 12 disease-related manifestations [fever, evanescent
rash, pleuritis, pneumonia, pericarditis, hepatomegaly, serum
ferritin levels (>3000 mg/L), lymphadenopathy, white blood
cells count (>15,000/mm), sore throat, myalgias, and arthritis].
Fever was defined by temperatures ≥39◦C; cutaneous rash was
considered positive if the patients presented an evanescent
salmon-pink, macular, or maculopapular rash predominantly
on the trunk and limbs. Pleuritis was defined as pleural
effusion linked with pleuritic pain; pericarditis was defined by
chest pain, pericardial friction rub, and effusion documented
by echocardiogram. Pneumonia was diagnosed in presence
of pulmonary consolidations documented by X-rays or chest
computed tomography (CT) scan. Lymphoadenopathy was
confirmed by ultrasound and/or CT scan in at least two different
sites. Diagnosis of hepatomegaly was confirmed by ultrasound
and/or CT and/or nuclear magnetic resonance spectroscopy
(NMR) scan findings. Leukocytosis was defined as a white
blood cell count ≥15,000/mm3; hyperferritinemia was defined
as serum ferritin ≥3000 ng/mL. ESR and CRP levels were
considered elevated when values fell beyond the laboratory
reference limit.
Response to anti IL-1 treatment was scored as complete,
partial, or failure. Response was considered complete or
provoking remission when signs of active disease were absent and
inflammatory markers were normalized. It was considered partial
when complete response was not achieved although there were
clear signs of clinical improvement according to the attending
physician.
Statistical Analysis
D’Agostino–Pearson’s test for normality was used. The normally
distributed variables were described by the mean ± standard
deviation (SD), and the non-normally distributed variables
using the median and range. Wilcoxon’s matched-pairs test and
paired t-tests were performed. Pearson’s and Spearman’s tests
were carried out to analyze the correlations where appropriate.
Univariate analysis of nominal variables was carried out using the
chi-square (χ2) test or Fisher’s exact-test where appropriate. The
P-values of two-tailed tests were calculated; p-values less than or
equal to 0.05 were considered significant.
The statistical calculations were performed using the
Statistical Package for Social Sciences 13.0 (SPSS, Chicago, IL,
United States).
RESULTS
The data from 140 AOSD patients (93 females and 47 males;
mean age at disease onset = 35.4 ± 17 years, mean age at
diagnosis = 37.4 ± 16.1 years) were evaluated. All the patients
were treated with ANA; four were later switched to CAN after
ANA failed. The mean disease duration before starting treatment
with ANA was 50.33 ± 81.67 months. Most of the patients
presented a systemic disease pattern (104/140, 74.2%) and the rest
presented a chronic articular one (36/140, 25.8%).
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Anakinra Treatment
Previous or Concomitant Therapies
Most of the patients were treated with NSAIDs, glucocorticoids
and/or DMARDs before starting ANA (Table 2). In the majority
of cases, steroids represented the first-line therapy (mean initial
dosage of prednisone (PDN) equivalent of 77.6± 186.3 mg daily).
DMARDs were employed in 120/140 (85.7%). Methotrexate
(MTX) was used in 91/120 (75.8%) and cyclosporine A (CyA)
in 50/120 cases (41.6%). ANA was adopted as a second-line
biological therapy (bDMARD) in 29/140 patients (20.7%); it was
the first-line biological treatment in 111/140 patients (79.3%).
As far as bDMARDs are concerned, anti-TNF-α therapies
represented the prevalent strategy and etanercept (ETN) and
infliximab (IFX) were the most frequently used drugs (79.3 and
44.8%, respectively). In the majority of cases (106/140, 75.8%),
ANA was prescribed in combination with other DMARDs; in
24.2% (34/140) it was used as a monotherapy (Figure 1). MTX
represented the first choice DMARD used in association with
ANA (Figure 1); in some cases (13/140, 9.2%), a combination of
more than one DMARD was utilized.
ANA Dosage
At baseline, 100 mg per day ANA was administered to 127/140
patients (90.7%); higher or lower doses were prescribed to 13/140
cases (9.3%). Four patients presented with a very aggressive
systemic form of the disease; 3 (23.1%) of these were originally
treated with 200 mg/day ANA and 1 (7.6%) was treated with
150 mg/day. In view of intolerability issues, nine patients were
prescribed lower, non-conventional dosages, i.e., 50 mg per day
(one case) or 100 mg every other day (eight cases).
TABLE 2 | Previous therapies prescribed to the Adult onset Still’s disease (AOSD)
patients before they began Anakinra (ANA) therapy.
Therapies % of patients
(n = 140)
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) 69.2
Steroids 97.8
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 85.7
Methotrexate (MTX) 75.8
Cyclosporine A (CyA) 41.6
Hydroxychloroquine (HCQ) 22.1
Colchicine 9.2
Azathioprine (AZA) 6.4
Salazopyrine (SSZ) 5.7
Leflunomide (LEF) 3.5
Biological therapies (bDMARDs) 20.7
Etanercept (ETN) 79.3
Infliximab (IFX) 44.8
Adalimumab (ADA) 20.6
Tocilizumab (TOCI) 6.8
Abatacept (ABA) 6.8
Golimumab (GOL) 6.8
Rituximab (RTX) 6.8
Certulizumab (CTZ) 6.8
FIGURE 1 | Concomitant therapies during ANA treatment. MTX,
methotrexate; CyA, cyclosporine A; HCQ, hydroxychloroquine; LEF,
leflunomide; SSZ, sulfasalazine.
Dosage was adjusted for 33/140 patients (23.5%) over
the course of treatment. In 29/33 cases showing marked
improvement, the dosage was reduced from 100 mg per day to
100 mg every other day. In 3/33 cases therapy was upgraded to the
standard 100 mg/day dose. In a single case, therapy was increased
from 100 mg to 200 mg per day in view of an incomplete clinical
response.
Duration of Therapy, Discontinuation, and AEs
After 12 months of treatment, 97/140 patients (69.2%) were
still receiving ANA. Overall, the mean duration of therapy was
35.7 ± 36.1 months. At the time, we analyzed the data, 69 out of
140 patients (49.3%) were still being treated with ANA, and 71
(50.7%) had discontinued therapy (Table 3).
The main reason for treatment discontinuation was linked
to the development of AEs (24/71 patients, 33.8%) followed
by remission (sustained disappearance of all clinical and
serological manifestations) in 20/71 cases (28.1%) (Figure 2).
Discontinuation for primary inefficacy was documented in 16/71
subjects (22.5%). ANA was discontinued in 11/71 cases (15.4%)
due to loss of efficacy during the follow-up.
AEs occurred in 47/140 patients (33.5%). The principal AE
reported was the appearance of in situ (28/47 cases, 59.5%) or
diffuse (12/47 cases, 25.5%) local reactions, usually in the form
of cutaneous urticarial lesions. Most of the patients abandoning
therapy because of AEs (18/24, 75%) did so because of severe
skin reactions. Infectious events (7/47 patients, 12.7%) were quite
rare: they consisted in three cases of pneumonia, three cases
of urinary tract infections and one case of recurrent dental
abscesses; infectious events caused withdrawal in two out of seven
cases.
The Clinical Efficacy of ANA
Anakinra proved to be effective in reducing all AOSD-linked
clinical and serological manifestations. Primary and secondary
inefficacy after 12 months was reported in 15/140 (10.7%)
and 11/140 (7.8%) patients, respectively. Pouchot’s score, which
was calculated at baseline and then at 3, 6, and 12 months,
demonstrated a significant improvement; there was a drop in
the mean score already at 3 months (5.5 ± 1.9, range 2–10, at
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TABLE 3 | The number of patients receiving ANA during the study period.
Baseline 3 months 6 months 12 months Time of this study
N◦ of patients (%) 140 (100%) 118 (84.2%) 109 (77.8%) 97 (69.2%) 69 (49.2%)
FIGURE 2 | Adverse events (AEs) linked to ANA.
FIGURE 3 | Changes in Pouchot’s score during the 12-months study period
in the ANA-treated patients.
baseline versus 1.1 ± 1.4, range 0–7, after 3 months; p < 0.0001)
(Figure 3).
An analysis of the prevalence of the disease’s main clinical
symptoms [fever, rash, pneumonia, pericarditis, pleuritis,
sorethroat, lymphadenopathy, hepatomegaly, myalgia, arthritis,
macrophage activation syndrome (MAS)] and laboratory features
(increased liver enzymes, hyperferritinemia, leucocytosis) at 3,
6, and 12 months uncovered a significant reduction in all of
these (p < 0.0001) beginning as early as 3 months into the
follow-up (Table 4). There were 98/140 (70%) patients who were
experiencing arthritis symptoms at baseline with a mean Disease
Activity Score 28 (DAS28) score of 4.7 ± 1.2 (range 1.4–7.29)
which fell significantly 3 months into therapy to 2.4± 1.08 (range
0.96–6.01) (p < 0.0001). After 12 months, the mean DAS28 score
fell even further reaching 1.7± 0.9 (0.49–6.8).
No differences in the clinical or serological response to
treatment were identified when the patients were stratified
according to age, sex or disease pattern (systemic or chronic
articular). Nor were differences observed when the patients
receiving ANA monotherapy were compared to those receiving
ANA combined with DMARDs or when the patients previously
treated with other biological drugs were compared with those
naïve to biological therapy.
Twelve (8.5%) patients showed signs of MAS before they were
prescribed ANA treatment. After therapy was begun, five cases
of MAS presented: one after 3 months (the patient recovered
without discontinuing ANA), one after 6 months (the patient
fully recovered without discontinuing therapy), 2 after 12 months
(one patient recovered and continued ANA therapy; the other
died). Another case of fatal MAS occurred after 16 months of
therapy and the patient underwent disseminated intravascular
coagulation (DIC); then the patient was successfully reanimated
after cardiac arrest. However, a new episode of MAS led to the
death of the patient who was still receiving ANA treatment 30
months later.
In one case a patient who was one of the 20 (14.2%) who
showed complete disease remission needed to begin ANA therapy
again. The other 19 cases are still in remission (mean follow-
up 56.8 ± 54 months): 9 (47.3%) are receiving only DMARDs
therapy, while 10 (52.7%) are completely drug-free.
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TABLE 4 | Clinical and laboratory features at baseline and during the 12-months study period in the ANA-treated patients.
Clinical and Laboratory Baseline (n = 140) (%) 3 months (n = 118) (%) 6 months (n = 109) (%) 12 months (n = 97) (%)
Fever 96.4 12.7 10 1
Rash 73.5 9.3 4.2 3
Pleuritis 14.2 1.6 3.6 2
Pneumonia 7.1 0 0 0
Pericarditis 17.8 0.8 0 0
Lymphadenopathy 51.4 12.7 4.5 3
Hepatomegaly or increased liver enzymes 47.1 9.3 5.5 5
Hyperferritinaemia 67.8 10.1 2.7 2
Leucocytosis 70 8.4 3.6 2
Sore throat 54.2 5 2.7 3
Myalgia 75 33 18.3 13.4
Arthritis 69.2 33 15.5 14.4
Macrophage Activation Syndrome (MAS) 8.5 0.8 0.9 1
FIGURE 4 | Modifications in ferritin levels during the 12-months study period
in the ANA-treated patients.
The Laboratory Efficacy of ANA
Laboratory parameters were significantly modified by therapy.
Ferritin serum levels were lower after 3 months of ANA
with respect to baseline data [397.5 ± 1072.68 ng/ml
(range 15–7581 ng/ml) versus 5965.97 ± 14677.48 ng/ml
(range 43–105000 ng/ml); p < 0.0001] and other
inflammatory markers including ESR and CRP showed
improved levels (Figure 4 and Table 5). Almost 33% of
the patients experienced liver involvement which was
confirmed by higher liver enzyme levels. Improvement was
noted already after 3 months of therapy (4.2% patients,
p < 0.0001).
The Impact of ANA on Concomitant Therapies during
the Follow-Up
Three months after beginning ANA therapy, the prevalence of
patients also receiving steroids was not significantly different
(97.8% patients at baseline versus 86.4% at the end of the
third month, p > 0.05). The mean dosage was significantly
lower (77.6 ± 186.3 mg of Prednisone (PDN) at baseline versus
8.8± 11.2 mg of PDN at the end of the third month; p < 0.0001).
After 12 months, the percentage of patients receiving steroid
therapy, which had fallen to 55.6%, was significantly different
(p < 0.001) (Table 6). The percentage of patients receiving
DMARD therapy had significantly fallen at the end of 12 months
(85.7% patients at baseline versus 59.7% at the end of the 12th
month, p < 0.001) and it fell even further (to 50.7%) at study
completion (Tables 6, 7).
Canakinumab Treatment
Four patients in whom ANA proved inefficacious were switched
to CAN. The mean age of these patients at onset was
34.2± 15.4 years; the mean age at diagnosis was 34.7± 13.3 years.
The mean duration of disease before starting CAN treatment was
58.33± 48.4 months. Three of these presented a systemic disease
pattern and one a chronic articular profile.
Previous or Concomitant Therapies
Two patients were receiving CAN in association with other
DMARDs, the other 2 were receiving monotherapy. The latter
were treated previously with other DMARDs including MTX,
hydroxychloroquine (HCQ) and CyA. Before starting ANA
treatment, three patients were unsuccessfully treated with other
bDMARDs: one was prescribed IFX, ETN, adalimumab, and
tocilizumab; another tocilizumab; the third adalimumab.
CAN Dosage, Therapy Duration, Reasons for
Discontinuing and AEs
Canakinumab was administered at the standard dose of 150 mg
every 8 weeks without dose adjustment neither at the beginning
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TABLE 5 | Laboratory features at baseline and during the 12-months study period in the ANA-treated patients.
Laboratory Baseline (n = 140) (%) 3 months (n = 118) (%) 6 months (n = 109) (%) 12 months (n = 97) (%)
Ferritin
>200 ng/ml 67.8 21.6 8.4 7.3
>1000 ng/ml 47.1 9.2 2.4 2.9
>3000 ng/ml 28.5 3 1.2 0
>10000 ng/ml 10 0 0 0
Eritrocyte sedimentation rate (ESR) 85 32.1 9.1 8.2
C-reactive protein (CRP) 90 30.5 12.8 8.2
Augmented liver enzymes 32.8 5 6.4 3
TABLE 6 | Concomitant therapy change during the 12-months study period in the ANA-treated patients.
Therapy Baseline (n = 140) 3 months (n = 118) 6 months (n = 109) 12 months (n = 97)
Steroids 97.8% 86.4% 68.8% 55.6%
77.6 ± 186.3 mg 8.8 ± 11.2 mg 5.2 ± 6.9 mg 3.4 ± 4.8 mg
DMARDs 85.7% 66.1% 59.6% 59.7%
TABLE 7 | Anakinra and canakinumab (CAN) therapy status after 12 months of
follow-up.
ANA CAN
Last Follow-up 32.2 ± 41.5 months 65.75 ± 76.34 months
Ongoing Therapy 49.2% (69/140) patients 50% (1/4) patients
Mean therapy duration 35.7 ± 36.1 months 22.1 ± 16.5 months
Ongoing steroids 31.8% (22/69) patients 100% (3/3) patients
Ongoing DMARDs 50.7% (35/69) patients 33.3% (1/3) patients
nor during the follow-up period. The mean duration of therapy
was 22.1 ± 16.5 months. Treatment is still ongoing in two
patients. In the other two cases, it was discontinued; in one case,it
was discontinued after 9 months because of loss of efficacy, in the
other it was discontinued after 45 months because of remission.
No AEs were registered in the CAN-treated patients.
CAN Clinical Efficacy
After 3 months of CAN therapy, Pouchot’s score fell significantly
from 4.25± 2.6 (range 2–8) to 1.25± 1.8 (range 1–4) (p< 0.0001)
(Figure 5). Despite a general improvement in symptoms, therapy
was discontinued in the chronic articular AOSD patient after
9 months because fever, arthritis and lymphadenopathy persisted
over time. We were thus able to evaluate clinical parameters at
12 months in only three patients (Table 8). In one case, after
6 months of therapy, disease symptoms flared up and led to
a MAS episode which was promptly treated and cured. The
patient continued CAN therapy after that episode, and treatment
is still ongoing. Signs of arthritis were observed at baseline in
2/4 patients; improvement was noted after 3 months in only
one patient who experienced a complete remission during the
follow-up. In all three remaining cases, there was no evidence at
12 months of clinical disease signs (no fever, rash, arthritis, or
lymphadenopathy).
The Laboratory Efficacy of CAN
Serum ferritin levels were increased at baseline in 2/4 patients and
were normalized after 3 months in all four. Serum ferritin levels
FIGURE 5 | Modifications in Pouchot’s score changes during the 12-months
study period in the CAN-treated patients.
were increased after 6 months in one patient who experienced
a MAS episode. As therapy was discontinued in one patient,
laboratory parameters after 12 months were assessed only in 3.
Ferritin levels in 2 of these appeared normal; in the third (the
same patient who experienced MAS 6 months earlier) ferritin
rose to 425 ng/ml. That same patient presented altered liver
enzyme, ESR, and CRP values throughout the observation period.
The transaminase levels were normal during follow-up in the
other three cases. ESR was elevated at baseline and at the end
of the third month in 3 of the 4 patients; it was reduced in
one patient after 6 months, and it was reduced in another after
12 months. CRP was also higher at baseline and after 3 months in
all of the patients, it was decreased in two patients at the 6 months
time point, and in another at the 12-months time point.
The Impact of CAN on Concomitant Therapies during
Follow Up
Although no patient discontinued steroids during the 12 months
study period, the mean PDN dosage was significantly lower with
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TABLE 8 | Clinical and laboratory features at baseline and during the 12-months study period in the CAN-treated patients.
Clinical and laboratory Baseline (n = 4) (%) 3 months (n = 4) (%) 6 months (n = 4) (%) 12 months (n = 3) (%)
Fever 100 25 50 0
Rash 50 0 0 0
Pleuritis 25 0 0 0
Pneumonitis 0 0 0 0
Pericarditis 25 0% 0 0
Lymphadenopathy 50 25 0 0
Hepatomegaly or increased liver enzymes 25 25 25 33.3
Hyperferritinemia 50 0 25% 33.3
Leucocytosis 100 25 25% 0
Sore throat 25 0 0% 0
Milagia 100 25 25% 0
Arthritis 50 25 50% 0
Macrophage Activation Syndrome (MAS) 0 0 25% 0
TABLE 9 | Changes in concomitant therapy strategies during the 12-months study period in the CAN-treated patients.
Therapy Baseline (n = 4) 3 months (n = 4) 6 months (n = 4) 12 months (n = 3)
Steroids 100% 100% 100% 100%
143.7 ± 238.2 mg 8.2 ± 7.8 mg 16.2 ± 13 mg 10 ± 7 mg
DMARDs 50% 50% 50% 33%
respect to the baseline value (143.75 ± 238.23 mg) as early as
at 3 months (8.2 ± 7.8 mg, p < 0.0001) and at 12 months
(10 ± 7.07 mg, p < 0.0001) (Table 9). The concomitant use of
DMARDs was similar at baseline (2/4 cases) and at the end of the
12 months follow-up period (1/3 cases) (Table 9). Information
regarding the current therapy and the last follow-up are outlined
in Table 7.
DISCUSSION
To our knowledge, this is the largest retrospective observational
study evaluating the efficacy and safety of ANA and CAN in
AOSD. Consistent with other studies, our data have confirmed
the efficacy of IL-1-INH treatment in AOSD patients. It is
well known that blocking IL-1, particularly IL-1β, represents
standard therapy for a number of autoinflammatory conditions
in which this cytokine plays a pivotal role. As far as IL-
1α or IL-1β signal cascades are concerned, upon binding to
the ligand-binding chain (IL-1RI), activation of the signaling
pathway originates from the cytoplasmic Toll/IL-1 receptor (TIR)
domain that associates with a TIR domain-containing adaptor,
MyD88. Subsequent phosphorylation of several kinases leads to
translocation of NF-κB to the nucleus and final expression of a
large portfolio of inflammatory genes (Weber et al., 2010). The
IL-1 family comprises 11 members (Dinarello, 2011), and some
investigators (Colafrancesco et al., 2012; Priori et al., 2014) have
shown that IL-1α/β and IL-18 are crucial in the pathogenesis
of AOSD and are valid serological biomarkers of the disease
(Colafrancesco et al., 2015).
First described as a treatment for AOSD in 2003, ANA, a
recombinant version of the interleukin 1 receptor antagonist
(IL1-RA), was the first IL-1 inhibitor used in clinical practice
(Rudinskaya and Trock, 2003). Although the efficacy of ANA
in AOSD has been described by several case-reports and case-
series, due to the disease’s rarity, large randomized control
trials (RCT) are still lacking. A meta-analysis published in 2014
identified eight studies, including one RCT (Nordström et al.,
2012) demonstrating that ANA seems to be effective in improving
AOSD manifestations and in reducing mean steroid dosage over
time in patients refractory to conventional therapies (Hong et al.,
2014). That meta-analysis, which considered all studies published
between 2010 and 2014 (sample size ranging from 6 to 28 patients
for a total of 134 patients receiving ANA treatment (100 mg/day),
showed an overall and complete remission rate of 81.66 and
66.75%, respectively, thus supporting the efficacy of ANA in more
than half of the patients studied.
The largest study until now evaluating ANA efficacy, which
analyzed 41 patients, was published in 2015. Approximately
68% of the patients were found to be responders; half achieved
complete remission defined as the total disappearance of signs
and symptoms of disease and normalization of laboratory
parameters. As reported in previous reports summarized in
Table 10 (Lequerré et al., 2008; Laskari et al., 2011; Nordström
et al., 2012; Giampietro et al., 2013; Gerfaud-Valentin et al.,
2014b; Cavalli et al., 2015; Ortiz-Sanjuán et al., 2015; Rossi-
Semerano et al., 2015), a complete remission was demonstrated
in up to 80% of the patients studied.
In our cohort of 140 patients a prompt response to IL-1
inhibitors was demonstrated already after 3 months. Both clinical
and laboratory parameters dramatically improved and remission
was sustained over time and led to discontinuation of treatment
in 28% of the cases during the follow-up. Most of the patients
succeeded in achieving remission within 3 months of beginning
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therapy, a finding that is in agreement with reports in the
literature describing the normalization of clinical, hematologic
and biochemical parameters within hours to days after the first
ANA injection. Pouchot’s score revealed a dramatic improvement
in patients’ general clinical condition within 3 months time.
Although the score lacks scientific validation, it is commonly
used to evaluate patients’ disease activity. Some investigators have
proposed using it as a “severity” rather than “activity” score.
Others have suggested giving it a prognostic value and of using
the score of 7.0 as a cut-off at the time of diagnosis as predictive
of a more severe outcome and an increased risk of mortality
(Ruscitti et al., 2016).
Interestingly, response to therapy was achieved rapidly in the
same way in the systemic and chronic articular patients studied
as far as the different signs and symptoms of the disease were
concerned.
The number of articular patients with arthritis symptoms as
well as the mean DAS 28 value significantly ameliorated over
the time. Although this aspect seems to be confirmed by other
studies (Laskari et al., 2011; Gerfaud-Valentin et al., 2014a), the
efficacy of ANA in improving articular manifestations continues
to be controversial. Laskari et al. (2011) demonstrated an
improvement in joint manifestations (evaluated by ACR50 and
ACR70 response) in 93 and 87% of their patients, respectively.
Although a very low number of treated patients (4 with a
systemic polyciclic pattern and 2 with a chronic articular one),
no difference in response to therapy was identified in the patient
groups by the study conducted by Gerfaud-Valentin et al. We
also reported on the apparent efficacy of ANA in 3 patients
with AOSD who was refractory to conventional therapies and
who showed marked improvement in joint manifestations after
therapy was begun (Priori et al., 2008). According to a study
by Cavalli et al. (2015), ANA proved to be more effective in
patients with the systemic disease pattern with respect to the
chronic articular one, especially in those cases experiencing
severe complications such as MAS.
The increased efficacy of ANA in patients experiencing a
prevalently systemic involvement is in line with a dichotomous
view of AOSD. Indeed, many assume that the systemic form
is mainly driven by IL-1 responsible for fever or increased
serum inflammatory marker, while the articular pattern is more
similar to rheumatoid arthritis and may be principally driven
by TNF-α (Maria et al., 2014). Likewise, in a study carried
out by Giampietro et al. (2013) the most impressive response
was obtained in the systemic AOSD pattern; a slightly less
dramatic effect was noted in the chronic articular phenotype.
Ortiz-Sanjuán et al. (2015) likewise reported a persistence of joint
involvement after one year of treatment in 41.5% of the patients
studied. Definitive conclusions on the real effectiveness of ANA
on joint involvement have yet to be drawn.
We did not observe any differences in the type of response
in the two patterns of the disease in our study nor when the
patients were stratified according to age, sex, and previous types
of therapies. Interestingly, no differences were noted in the AOSD
group receiving monotherapy with respect to those who were also
receiving DMARDs. The fact that similar results were reported
by Giampietro et al. (2013) seems to confirm the relevance of
taking into consideration the cost-effectiveness of ANA in view
of its efficacy as monotherapy and its steroid sparing effect. For
the time being, there is no consensus on this issue. Although
the differences were not significant in a study by Ortiz-Sanjuán
et al. (2015) focusing on the use of ANA in combination with
conventional immunosuppressive drugs, it did not appear to
improve the systemic symptoms or joint manifestations more
efficaciously than did the monotherapy. ANA seems to spare
steroids with the non-negligible consequence of preventing
complications attributable to the chronic intake of steroids.
In most published studies ANA was used at the standard
dose of 100 mg per day. In our study, a few of the patients
began with lower dosages (50 mg per day or 100 mg every other
day). Those patients were for the most part the ones who later
needed dosage upgrade to the conventional one. We also reported
on one patient whose 100 mg per day dosage did not appear
to be sufficiently effective; when dosage was later switched to
200 mg/day the patient showed a good response and tolerability.
In the presence of a clinical improvement, ANA dose has been
reduced in several cases of our cohort, more commonly than in
other reports (Laskari et al., 2011; Gerfaud-Valentin et al., 2014b;
Ortiz-Sanjuán et al., 2015).
The optimal duration of ANA treatment in AOSD has
not yet been established. As we recently reported in another
multicenter study, the off-label use of IL-1 inhibitors presents
a wide variability. While they are more frequently employed at
a dosage based on body weight in pediatric patients, in adults
a standard dose of 100 mg is frequently used (Vitale et al.,
2016). Contrary to our observations, Kötter et al. described a
recurrence in disease activity after reducing ANA administration
to alternate days (Kötter et al., 2007). During a previous study
focusing on the use of IL-1 inhibitors in different conditions,
we noted that adjusting the dosage by increasing the dose at
each administration or decreasing the timing between injections
proved to be successful in 66.7% of patients. With one exception,
we did not report any relapse after therapy was discontinued
because of remission. In agreement with other reports, tapering
of dosage was well tolerated and there was no evidence of relapse
(Laskari et al., 2011; Giampietro et al., 2013; Ortiz-Sanjuán et al.,
2015; Vitale et al., 2016).
The current study was able to retrospectively evaluate not
only the efficacy but also the safety of ANA. In agreement with
our previous reports (Sfriso et al., 2016; Vitale et al., 2016) and
those of others (outlined in Table 10), ANA appears to be a safe
drug that does not pose risks of infections. In the current study,
the frequency of AEs was higher (33.5%) then that previously
reported (Table 10). The most relevant AEs noted were reactions
at the injection site (28/140 cases, 20%) or diffuse allergic skin
rashes (12/140 cases, 8.6%); in some cases, the AEs were so
severe as to determine therapy discontinuation. Although with
a lower frequency, cutaneous reactions were the most commonly
reported AE even in other reports (Table 10). In the light of the
current study (the largest cohort of patients carried out until now)
and the findings of others, the risk of reactions must be taken into
consideration when therapy is being decided. The short half-life
of ANA and the need for daily subcutaneous injections are other
not negligible disadvantages that also need to be considered.
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Canakinumab is a fully human monoclonal antibody against
IL-1β with a longer half-life (26 days), meaning that it can be
administered every 8 weeks. It has been approved for periodic
fevers such as Cryopyrin Associated Periodic Syndromes (CAPS)
as well as for SJIA. Promising results have recently been reported
in patients with AOSD refractory to ANA. The first report,
which was published in 2012 (Kontzias and Efthimiou, 2012),
was followed by others (Barsotti et al., 2014; Lo Gullo et al.,
2014). Although a study by Rossi-Semerano et al. (2015) did not
report any significant differences in AEs in the ANA and CAN
therapy groups, no AEs occurred in our 4 patients who were
treated with CAN. Indeed, no cutaneous reactions or infections
of any kind were noted. CAN proved to be effective in 3/4
patients and perhaps responsible for therapy discontinuation
due to complete remission in one. It should be underlined
that the failure took place in a patient with a chronic articular
pattern. Although a slight improvement in the patient’s general
condition was noted in that case, neither arthritis nor fever
responded to therapy. In another case regarding a patient
with a systemic pattern but also showing signs of arthritis,
CAN proved to be efficacious. Definite conclusions concerning
CAN efficacy in inflammatory joint involvement are not yet
possible.
One patient also experienced MAS during therapy but
completely recovered and subsequently continued therapy.
Episodes of MAS also occurred during ANA treatment, in two
cases with fatal outcomes. Although the percentage of patients
experiencing recrudescence of the disease with severe life-
threatening complications was quite low [6/140 (4.1%) = 5 cases
during ANA treatment and 1 during CAN therapy], neither of the
IL-1 inhibitors appeared to be capable of completely controlling
these severe systemic manifestations.
Although the retrospective design and the open-label nature
constitute potential limitations, the study represents the largest
evaluation of IL-1 inhibition efficacy and safety in patients
with AOSD. According to our findings, IL-1-INH seem to
represent the best bDMARDs available and should be considered
the first-line biologic treatment for patients not responding
to conventional treatment. ANA can also be utilized as a
monotherapy since it seems to have the same efficacy even when
it is not associated to DMARDs. As ANA seems to be effective
in improving all the clinical and laboratory features of AOSD,
its use seems opportune regardless of the disease pattern. ANA
also appears to be safe as far as the infectious risk is concerned.
It should nevertheless be remember that development of skin
reactions can at times be so invalidating as to induce therapy
discontinuation.
Canakinumab also appears to be effective in AOSD, but in
the current study it was possible to evaluate its efficacy only in
patients who did not respond to ANA therapy or in whom ANA
efficacy was lost. It cannot be excluded that those cases were more
aggressive ones. It was also impossible to make any comparisons
between ANA and CAN given the overwhelming differences in
numbers.
CONCLUSION
Interleukin-1 inhibitors appear to be a highly effective treatment
of AOSD. Although most data regarding the effect of IL-1-INH
in AOSD concern ANA, case reports focusing on treatment with
CAN suggest that it has a similar efficacy. Further studies and
randomized controlled trials are of course warranted.
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